Conceptus Goes Red
Conceptus (NAS: CPTS) filed its 10-K on Thursday. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Conceptus met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank, and GAAP earnings per share dropped to a loss.
Gross margins grew, operating margins shrank, and net margins contracted.
Conceptus reported revenue of $33.5 million. The 10 analysts polled by S&P Capital IQ expected a top line of $33.2 million on the same basis. GAAP reported sales were 8.4% lower than the prior-year quarter's $36.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.08. The five earnings estimates compiled by S&P Capital IQ predicted $0.02 per share. GAAP EPS were -$0.08 for Q4 versus $2.66 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 83.5%, 160 basis points better than the prior-year quarter. Operating margin was -8.4%, 2,520 basis points worse than the prior-year quarter. Net margin was -7.6%, 23,630 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $28 million. On the bottom line, the average EPS estimate is -$0.13.
Next year's average estimate for revenue is $135.6 million. The average EPS estimate is $0.04.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 79 members rating the stock outperform and 13 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 22 give Conceptus a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Conceptus is outperform, with an average price target of $14.22.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Conceptus the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Conceptus to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.